Intellipharmaceutics International Inc (IPCI) 2.84 $IPCI
Intellipharmaceutics Reports That the FDA Has Given Its Toronto Manufacturing Facility an "Acceptable" Classification
GlobeNewswire - Mon Oct 27, 6:15AM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the United States Food and Drug Administration ("FDA"
has provided the Company with written notification that its Toronto, Canada manufacturing facility has received an "acceptable" classification.
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin(TM) XR (Pregabalin Extended-Release)
GlobeNewswire - Wed Oct 22, 4:15PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today provided an update on the progress of its Regabatin(TM) XR product development. Regabatin(TM) XR pregabalin extended release capsules are the Company's non-generic pregabalin formulations. The Company intends to present the following information arising from its Regabatin(TM) XR product development program at the upcoming American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Diego from Nov 2-6, 2014.
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04), PFE: 29.95 (+0.11)
OTC Daily Alert Stock Watch - Intellipharmaceutics International Inc. (NASDAQ: IPCI)
WorldStockWire - Sun Oct 19, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
IPCI: 2.84 (+0.04)
Intellipharmaceutics posts lower Q3 2014 net loss of USD1.7m
M2 - Thu Oct 16, 7:55AM CDT
Pharmaceutical company Intellipharmaceutics International (TSX:I) disclosed on Wednesday its net loss of USD1.7m (USD0.07 per common share) for the three months ended 31 August 2014.
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
Intellipharmaceutics Announces Third Quarter 2014 Results
GlobeNewswire - Wed Oct 15, 3:51PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
Profound Medical Appoints Shameze Rampertab as Chief Financial Officer
GlobeNewswire - Wed Oct 15, 6:00AM CDT
Profound Medical Inc., a medical device company developing and commercializing a unique, minimally invasive treatment for prostate cancer, today announced it has named Shameze Rampertab to the position of Chief Financial Officer. Prior to this appointment, Mr. Rampertab was the VP of Finance and Chief Financial Officer of Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I).
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
Intellipharmaceutics reports departure of CFO Shameze Rampertab on 10 October 2014
M2 - Wed Oct 01, 6:07AM CDT
Pharmaceutical company Intellipharmaceutics International (TSX:I) stated on Wednesday that its vice president, Finance and chief financial officer, Shameze Rampertab, is stepping down on 10 October 2014 to pursue an opportunity in the medical devices industry.
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
Intellipharmaceutics Announces Resignation of Chief Financial Officer
GlobeNewswire - Tue Sep 30, 4:25PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the resignation of Shameze Rampertab, Vice President, Finance and Chief Financial Officer, who is leaving the Company effective October 10, 2014 to pursue an opportunity in the medical devices industry.
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
Will IntelliPharmaCeutics (IPCI) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 10:37AM CDT
Will IntelliPharmaCeutics (IPCI) Continue to Surge Higher?
IPCI: 2.84 (+0.04)
IntelliPharmaCeutics (IPCI) in Focus: Stock Gains 15.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 8:25AM CDT
IntelliPharmaCeutics (IPCI) was a big mover last session, with shares rising nearly 16% on the day.
MNK: 92.18 (-0.65), ENDP: 66.92 (+0.63), LCI: 56.72 (+0.83), IPCI: 2.84 (+0.04)
Intellipharmaceutics' Oxycodone Program to Prevent Overdose - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 4:10PM CDT
Intellipharmaceutics (IPCI) upgraded its Rexista oxycodone development program.
ENDP: 66.92 (+0.63), IPCI: 2.84 (+0.04), GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60)
Intellipharmaceutics Augments Its Rexista(TM) Oxycodone Development Program With Novel Overdose Deterrence Technology
GlobeNewswire - Thu Aug 28, 3:43PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced an enhancement of its Rexista(TM) abuse-deterrence technologies with a significant improvement designed to prevent overdose when more pills than prescribed are swallowed intact. Intellipharmaceutics' new platform technology is branded PODRAS(TM) (Paradoxical OverDose Resistance Activating System).
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
IntelliPharmaCeutics (IPCI): Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 29, 10:14AM CDT
IntelliPharmaCeutics (IPCI): Moving Average Crossover Alert
IPCI: 2.84 (+0.04)
5 Stocks Ready for Breakouts
at The Street - Mon Jul 28, 8:16AM CDT
These stocks look poised to break out and trade higher from current levels.
ALDR: 17.91 (+1.10), IPCI: 2.84 (+0.04), RCPT: 103.65 (+1.93), CDXS: 2.56 (+0.01), TWOU: 18.20 (+0.32), DRL: 5.81 (-0.04)
Why Intellipharmaceutics (IPCI) Stock Is Down Today
at The Street - Wed Jul 09, 2:41PM CDT
Intellipharmaceutics (IPCI) plunged Wednesday after Maxim Group downgraded the stock to "hold" from "buy" and decreased its price target to $3 from $7.
IPCI: 2.84 (+0.04)
IntelliPharmaCeutics International (IPCI) Crumbles: Stock Plunges by 13.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:30AM CDT
IntelliPharmaCeutics International has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
SGYP: 3.43 (-0.15), BCRX: 11.72 (-0.34), IPCI: 2.84 (+0.04), AERI: 25.22 (+0.43)
Intellipharmaceutics Announces Second Quarter 2014 Results
GlobeNewswire - Mon Jul 07, 5:00PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics, Delcath Systems, Valeant Pharma and Alkermes
PR Newswire - Fri Mar 21, 4:39PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to reach 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day 0.02% lower at 686.29, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and Alkermes PLC (NASDAQ: ALKS). Free technical research on IPCI, DCTH, VRX and ALKS can be downloaded upon signing up at:
VRX: 133.04 (+1.53), IPCI: 2.84 (+0.04), ALKS: 50.55 (-0.74), DCTH: 1.66 (-0.08), VRX.TO: 149.80 (+2.53)
IntelliPharmaCeutics International (IPCI) Soars: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose over 9% on the day.
CRME: 7.92 (-0.08), IPCI: 2.84 (+0.04), WX: 37.70 (-0.05), BLRX: 1.39 (-0.01)
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:44AM CDT
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue?
IPCI: 2.84 (+0.04)
Intellipharmaceutics Reports That the FDA Has Given Its Toronto Manufacturing Facility an "Acceptable" Classification
GlobeNewswire - Mon Oct 27, 6:15AM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the United States Food and Drug Administration ("FDA"
has provided the Company with written notification that its Toronto, Canada manufacturing facility has received an "acceptable" classification. I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin(TM) XR (Pregabalin Extended-Release)
GlobeNewswire - Wed Oct 22, 4:15PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today provided an update on the progress of its Regabatin(TM) XR product development. Regabatin(TM) XR pregabalin extended release capsules are the Company's non-generic pregabalin formulations. The Company intends to present the following information arising from its Regabatin(TM) XR product development program at the upcoming American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Diego from Nov 2-6, 2014.
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04), PFE: 29.95 (+0.11)
OTC Daily Alert Stock Watch - Intellipharmaceutics International Inc. (NASDAQ: IPCI)
WorldStockWire - Sun Oct 19, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
IPCI: 2.84 (+0.04)
Intellipharmaceutics posts lower Q3 2014 net loss of USD1.7m
M2 - Thu Oct 16, 7:55AM CDT
Pharmaceutical company Intellipharmaceutics International (TSX:I) disclosed on Wednesday its net loss of USD1.7m (USD0.07 per common share) for the three months ended 31 August 2014.
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
Intellipharmaceutics Announces Third Quarter 2014 Results
GlobeNewswire - Wed Oct 15, 3:51PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
Profound Medical Appoints Shameze Rampertab as Chief Financial Officer
GlobeNewswire - Wed Oct 15, 6:00AM CDT
Profound Medical Inc., a medical device company developing and commercializing a unique, minimally invasive treatment for prostate cancer, today announced it has named Shameze Rampertab to the position of Chief Financial Officer. Prior to this appointment, Mr. Rampertab was the VP of Finance and Chief Financial Officer of Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I).
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
Intellipharmaceutics reports departure of CFO Shameze Rampertab on 10 October 2014
M2 - Wed Oct 01, 6:07AM CDT
Pharmaceutical company Intellipharmaceutics International (TSX:I) stated on Wednesday that its vice president, Finance and chief financial officer, Shameze Rampertab, is stepping down on 10 October 2014 to pursue an opportunity in the medical devices industry.
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
Intellipharmaceutics Announces Resignation of Chief Financial Officer
GlobeNewswire - Tue Sep 30, 4:25PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the resignation of Shameze Rampertab, Vice President, Finance and Chief Financial Officer, who is leaving the Company effective October 10, 2014 to pursue an opportunity in the medical devices industry.
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
Will IntelliPharmaCeutics (IPCI) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 10:37AM CDT
Will IntelliPharmaCeutics (IPCI) Continue to Surge Higher?
IPCI: 2.84 (+0.04)
IntelliPharmaCeutics (IPCI) in Focus: Stock Gains 15.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 8:25AM CDT
IntelliPharmaCeutics (IPCI) was a big mover last session, with shares rising nearly 16% on the day.
MNK: 92.18 (-0.65), ENDP: 66.92 (+0.63), LCI: 56.72 (+0.83), IPCI: 2.84 (+0.04)
Intellipharmaceutics' Oxycodone Program to Prevent Overdose - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 4:10PM CDT
Intellipharmaceutics (IPCI) upgraded its Rexista oxycodone development program.
ENDP: 66.92 (+0.63), IPCI: 2.84 (+0.04), GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60)
Intellipharmaceutics Augments Its Rexista(TM) Oxycodone Development Program With Novel Overdose Deterrence Technology
GlobeNewswire - Thu Aug 28, 3:43PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced an enhancement of its Rexista(TM) abuse-deterrence technologies with a significant improvement designed to prevent overdose when more pills than prescribed are swallowed intact. Intellipharmaceutics' new platform technology is branded PODRAS(TM) (Paradoxical OverDose Resistance Activating System).
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
IntelliPharmaCeutics (IPCI): Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 29, 10:14AM CDT
IntelliPharmaCeutics (IPCI): Moving Average Crossover Alert
IPCI: 2.84 (+0.04)
5 Stocks Ready for Breakouts
at The Street - Mon Jul 28, 8:16AM CDT
These stocks look poised to break out and trade higher from current levels.
ALDR: 17.91 (+1.10), IPCI: 2.84 (+0.04), RCPT: 103.65 (+1.93), CDXS: 2.56 (+0.01), TWOU: 18.20 (+0.32), DRL: 5.81 (-0.04)
Why Intellipharmaceutics (IPCI) Stock Is Down Today
at The Street - Wed Jul 09, 2:41PM CDT
Intellipharmaceutics (IPCI) plunged Wednesday after Maxim Group downgraded the stock to "hold" from "buy" and decreased its price target to $3 from $7.
IPCI: 2.84 (+0.04)
IntelliPharmaCeutics International (IPCI) Crumbles: Stock Plunges by 13.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:30AM CDT
IntelliPharmaCeutics International has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
SGYP: 3.43 (-0.15), BCRX: 11.72 (-0.34), IPCI: 2.84 (+0.04), AERI: 25.22 (+0.43)
Intellipharmaceutics Announces Second Quarter 2014 Results
GlobeNewswire - Mon Jul 07, 5:00PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
I.TO: 3.15 (+0.02), IPCI: 2.84 (+0.04)
Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics, Delcath Systems, Valeant Pharma and Alkermes
PR Newswire - Fri Mar 21, 4:39PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to reach 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day 0.02% lower at 686.29, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and Alkermes PLC (NASDAQ: ALKS). Free technical research on IPCI, DCTH, VRX and ALKS can be downloaded upon signing up at:
VRX: 133.04 (+1.53), IPCI: 2.84 (+0.04), ALKS: 50.55 (-0.74), DCTH: 1.66 (-0.08), VRX.TO: 149.80 (+2.53)
IntelliPharmaCeutics International (IPCI) Soars: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose over 9% on the day.
CRME: 7.92 (-0.08), IPCI: 2.84 (+0.04), WX: 37.70 (-0.05), BLRX: 1.39 (-0.01)
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:44AM CDT
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue?
IPCI: 2.84 (+0.04)
